- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04032691
PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol
The Effects of Alpha-2 Adrenergic Receptor Modulation on Rates of Carbon-11 Butanol Clearance From Ventricular Cerebrospinal Fluid
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This will be an open label pilot study of feasibility in healthy volunteers with no therapeutic intent. Vital signs, electrocardiogram (ECG) parameters, and sleep quality will be measured repeatedly during a one week lead-in period. Then, the ventricular cerebrospinal fluid (vCSF) clearance rates of [11C]butanol will be measured with PET before and after one week of treatment with clonidine, 0.1 mg by mouth daily at bedtime. Safety surveillance will be augmented with home health monitoring devices that are wifi and blue tooth enabled. Surveillance for adverse events related to drug discontinuation will be monitored for one week during a washout period.
Primary Objective: To assess the logistical feasibility and safety of treating normotensive adults with clonidine and monitoring its effects with home health devices. The primary outcome measure will be the number of adverse events (AEs) or serious adverse events (SAEs). Other measures will include changes in sleep quality, vital signs and ECG parameters, such as the PR and corrected QT intervals.
Secondary Objectives: To estimate drug-induced changes in vCSF clearance rates of butanol with PET scans acquired before and after treatment as a function of steady-state plasma levels of clonidine.
Undersøgelsestype
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Weill Cornell Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Able to give informed consent. No vulnerable populations.
- Age 18-to-89 years old
- Mini-Mental Status Examination of ≥ 28
- Confirmed by the screening procedures to still be reasonably healthy and, in the opinion of the investigators, likely to tolerate the imaging procedures. For example, patients with chronic low back pain might not be able to lie still for very long.
- Confirmed by the screening procedures to have normal hemodynamic function. Systolic blood pressure and pulse must be higher than 120 mmHg and 60 beats per minute (bpm) while sitting. At the discretion of the investigators, athletic people who engage in vigorous exercise of one hour or more at least four times per week may be enrolled if their systolic blood pressure and pulse are higher than 100 mmHg and 50 beats per minute while sitting.
- Unremarkable electrocardiograms with PR intervals of less than 200 mSec and QT interval corrected with Frederica's method (QTcF) of less than 440 mSec.
- Willing and able to refrain from abusing any recreational drugs, including marijuana because of its sleep effects, and drink less than one unit of alcoholic beverages per day starting one week prior to the lead-in period, and avoided for the next three weeks while on study (the one week lead-in period, one week on drug period, and one week washout period).
- Willing to refrain from donating blood during the month of study (because of its potential effect of quickening pulse).
- Willing to refrain from participating in any other research study that requires taking medication during the month of study.
- Willing to refrain from being vaccinated during the month of study.
- Have not participated in research with exposure to ionizing radiation that would result in approaching the exposure limits for healthy volunteers described in the Code of Federal Regulations, Title 21 Part 361.1 (21CFR361.1)
Exclusion Criteria:
- History of allergy to clonidine.
- History of multiple hypersensitivity reactions, as indicated by allergies to multiple medications, foods, and seasonal pollens.
- History or physical examination suggestive of a condition, disorder, or disease that could represent a contra-indication to taking an antihypertensive. The relative contraindications to clonidine listed in the package insert under the section on precautions will be exclusionary in this study. They include subjects with coronary artery insufficiency syndromes, histories of myocardial infarction, cardiac conduction abnormalities, cerebrovascular disease, and chronic renal failure.
- Women who are pregnant or breast feeding will not be eligible to participate in the study, as clonidine is classified as a Class C risk to a fetus. (In fact, there is a safety signal in pregnant animal models that justifies exclusion, even if the signal is weak.)
- History, physical examination or clinical laboratory test result suggestive of a condition, disorder, or disease that could affect the adsorption, distribution, metabolism or excretion of clonidine, including an alcohol abuse or dependence disorder.
- Positive urine toxicology screen for drugs other than cannabis.
- Subjects may not be a member of a vulnerable population.
- May not have donated blood in the 30 days prior to the start of the lead-in period.
- May not have participated in research administering drugs in the last 30 days.
- May not have been vaccinated in the 30 days prior to the start of the lead-in period.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Clonidine Pill
0.1 mg by mouth daily at bedtime for one week
|
0.1 mg by mouth daily at bedtime for one week
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Adverse Events
Tidsramme: one week on drug
|
Clinically significant changes in hemodynamic function, including vital signs (VSs) and ECG parameters, will be classified as adverse events.
|
one week on drug
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in Ventricular CSF Clearance Rates of [11C]Butanol
Tidsramme: after one week on drug compared to drug free baseline rates
|
The rate of change in the concentration of radioactivity as a function of time before drug treatment compared to after drug treatment.
|
after one week on drug compared to drug free baseline rates
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Sleep Quality: Duration
Tidsramme: Average of one week before drug compared to one week on drug, and one week after drug.
|
Time interval between falling asleep and waking up as estimated with a wearable sleep tracker.
|
Average of one week before drug compared to one week on drug, and one week after drug.
|
Sleep Quality: Time in Deep Sleep
Tidsramme: Average of one week before drug compared to one week on drug, and one week after drug.
|
Sum of time intervals classified as representing deep sleep by a wearable sleep tracker.
|
Average of one week before drug compared to one week on drug, and one week after drug.
|
Sleep Quality: number of nocturnal awakenings
Tidsramme: Average of one week before drug compared to one week on drug, and one week after drug.
|
Number of times that nocturnal activity is classified as an awakening by a wearable sleep tracker.
|
Average of one week before drug compared to one week on drug, and one week after drug.
|
Sleep Quality: Subjective Self Rating of Quality
Tidsramme: Component and global scale scores on Day 1 (before drug) compared to score on Day 2 (after first dose of drug), Day 8 (after one week on drug) and Day 16 (after one week of washout).
|
Score on each component and the "global" sum of subscale scores on the Pittsburgh Sleep Quality Index (PSQI), where the range of scores on the seven components varies from 0 (good sleep) through 3 (bad sleep).
|
Component and global scale scores on Day 1 (before drug) compared to score on Day 2 (after first dose of drug), Day 8 (after one week on drug) and Day 16 (after one week of washout).
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: P. David Mozley, MD, Weill Medical College of Cornell University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Antihypertensive midler
- Autonome agenter
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Adrenerge alfa-2-receptoragonister
- Adrenerge alfa-agonister
- Adrenerge agonister
- Sympatolytika
- Clonidin
Andre undersøgelses-id-numre
- 19-05020048
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- Studieprotokol
- Klinisk undersøgelsesrapport (CSR)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Clonidine Pill
-
FloralisGroupe Hospitalier Mutualiste de GrenobleAfsluttetAnkelforstuvning | Divertikulit | Pyelonefritis | Prostatitis | Infektiøs colitis | PneumonitisFrankrig
-
ImplenomicsPopulation Council; RTI International; Society of Clinical and Radiation...Ikke rekrutterer endnuLivmoderhalskræft | Non Hodgkin lymfom | Kaposi Sarkom
-
InnFocus Inc.AfsluttetPrimær åbenvinkelglaukomFrankrig
-
University of the Incarnate WordAfsluttetSyndromer med tørre øjne | Meibomisk kirtel dysfunktion | Okulær overfladesygdomForenede Stater
-
University of AlcalaHospital Universitario de FuenlabradaRekrutteringGraviditetsresultat | Diagnostisk billeddannelse | Biomekanik | Ryglidelse | Biomedicinsk teknologiSpanien
-
University of California, San FranciscoMerck Sharp & Dohme LLC; OncoSec Medical IncorporatedAfsluttet
-
InnFocus Inc.AfsluttetPrimær åbenvinkelglaukomFrankrig, Holland, Spanien, Schweiz
-
Assistance Publique - Hôpitaux de ParisAfsluttetFosterinfektion | Cytomegalovirus (CMV) infektionFrankrig
-
BioDelivery Sciences InternationalAfsluttetNeuropati | Smertefuld diabetisk neuropati | Diabetisk neuropatiForenede Stater
-
OnxeoSimbec ResearchAfsluttetFase 1 PK, biotilgængelighed, sikkerhedsundersøgelse af clonidin MBT w Catapres hos raske frivilligeSund og raskDet Forenede Kongerige